Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Naoaki Watanabe (Tokyo, Japan), Naoaki Watanabe, Ryota Satou, Nobuharu Ohshima, Masahiro Kawashima, Kazuko Miyakawa, Ayumi Mitsune, Masahiro Ohgiya, Kenichi Okuda, Takahiro Ando, Aika Suzuki, Junko Suzuki, Kimihiko Masuda, Akira Yamane, Atsuhisa Tamura, Hideaki Nagai, Shinobu Akagawa, Hirotoshi Matsui, Nobuyuki Kobayashi, Ken Ohta. Efficacy and safety of kanamycin addition in patients with drug-refractory mycobacterium avium complex lung disease. Eur Respir J 2015; 46: Suppl. 59, 2633

Member's Comments

No comment yet.

Related content which might interest you: Treatment of refractory mycobacterium avium complex lung disease with a moxifloxacin-containing regimen Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Treatment outcomes of macrolide-resistant mycobacterium avium complex lung disease Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016 Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease Source: Eur Respir J, 55 (4) 1901240; 10.1183/13993003.01240-2019 Year: 2020 Efficacy and safety of bronchial artery embolization for the control of hemoptysis in patients with mycobacterium avium complex lung disease Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014 Retrospective observation of mycobacterium avium complex lung disease followed without treatment Source: Annual Congress 2013 –Non-tuberculous mycobacteria: clinical management Year: 2013 Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020 Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018 Treatment of severe Mycobacterium avium complex pulmonary disease with a adjunctive amikacin and clofazimine versus standard regimen alone, a retrospective study Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection I Year: 2019 A randomized, open-label, multicenter study of liposomal amikacin for inhalation in adult patients with nontuberculous mycobacteria (NTM) lung infections caused by mycobacterium avium complex (MAC) Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systemic review and meta-analysis Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection Year: 2019 Durability of culture conversion in patients receiving Amikacin Liposome Inhalation Suspension (ALIS) for treatment-refractory Mycobacterium avium complex lung disease (MAC-LD) in the CONVERT study Source: International Congress 2019 – Advances in bronchiectasis and non-TB mycobacterial infections Year: 2019 Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019 Year: 2019 Factors related to response to intermittent treatment of mycobacterium avium complex lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 557s Year: 2006 Retrospective investigation of patients positive for glycopeptidolipid-core antibody to mycobacterium avium complex pulmonary disease Source: International Congress 2014 – Tuberculosis: diagnosis Year: 2014 Isolation of M. abscessus from patients with M. avium complex (MAC) lung disease Source: Annual Congress 2013 –Bacterial, fungal and mycobacterial infections Year: 2013 Clinical relevance of Mycobacterium simiae in pulmonary samples Source: Eur Respir J 2008; 31: 106-109 Year: 2008 A double blind randomized study of aminoglycoside infusion with combined therapy for pulmonary mycobacterium avium complex disease Source: Annual Congress 2006 - Clinical epidemiology of tuberculosis Year: 2006 Analysis of clinical course after pulmonary resection for mycobacterium avium complex lung disease in our hospital Source: International Congress 2014 – Infection, thoracic trauma and congenital lesions Year: 2014 Characteristics of patients with isolation of mycobacterium xenopi Source: Annual Congress 2013 –Non-tuberculous mycobacteria: clinical management Year: 2013 Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment Source: Eur Respir J 2003; 21: 478-482 Year: 2003